Dosimetric comparison of intensity modulated and volumetric arc radiation therapy for gastric cancer

Li,Zhiping; Zeng,Jianshuang; Wang,Zi; Zhu,Hong; Wei,Yuquan

doi:10.3892/ol.2014.2363

Dosimetric comparison of intensity modulated and volumetric arc radiation therapy for gastric cancer

Authors:
- Zhiping Li
- Jianshuang Zeng
- Zi Wang
- Hong Zhu
- Yuquan Wei
View Affiliations

Affiliations: Department of Abdominal Oncology, Cancer Center of West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: July 18, 2014 https://doi.org/10.3892/ol.2014.2363
Pages: 1427-1434

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to compare radiotherapy treatment plans for gastric cancer using intensity‑modulated radiotherapy (IMRT) and single/double‑arc volumetric modulated arc therapy (SA/DA‑VMAT) delivery techniques. A total of 29 postoperative gastric cancer patients were enrolled in this study and each patient was scheduled 5‑field IMRT (5F‑IMRT), 7‑field IMRT (7F‑IMRT), SA‑VMAT and DA‑VMAT techniques. Dose‑volume histogram statistics, conformal index (CI), homogeneity index (HI) and monitor units (MUs) were analyzed to compare treatment plans. The DA‑VMAT plans exceeded the other three methods in terms of planning tumor volume dose and organs at risk in the kidneys, but not in the liver. DA‑VMAT exhibited a better mean CI (0.87±0.03) and HI (0.10±0.01) than the other techniques. In addition, for the kidneys the dose sparing (V13, V18 and mean kidney dose) was improved by DA‑VMAT plans. Similar results were observed for MUs. However, 5F‑IMRT showed a marginal advantage in V30 and mean dose in normal liver when compared with DA‑VMAT. The results of this study suggest that DA‑VMAT provides improved tumor coverage when compared with 5F‑IMRT, 7F‑IMRT and SA‑VMAT; however, DA‑VMAT exhibits no advantage in liver protection when compared with 5F‑IMRT. Further studies are required to establish differences in treatment outcomes among the four technologies.

View Figures

View References

1	Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 24:2137–2150. 2006.
2	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
3	Macdonald JS, Smalley SR, Benedetti J, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 345:725–730. 2001.
4	Kim S, Lim DH, Lee J, et al: An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys. 63:1279–1285. 2005.
5	Ringash J, Khaksart SJ, Oza A, et al: Post-operative radiochemotherapy for gastric cancer: adoption and adaptation. Clin Oncol (R Coll Radiol). 17:91–95. 2005.
6	Alani S, Soyfer V, Strauss N, Schifter D and Corn BW: Limited advantages of intensity-modulated radiotherapy over 3D conformal radiation therapy in the adjuvant management of gastric cancer. Int J Radiat Oncol Biol Phys. 74:562–566. 2009.
7	Minn AY, Hsu A, La T, et al: Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer. Cancer. 116:3943–3952. 2010.
8	Dahele M, Skinner M, Schultz B, Cardoso M, Bell C and Ung YC: Adjuvant radiotherapy for gastric cancer: A dosimetric comparison of 3-dimensional conformal radiotherapy, tomotherapy and conventional intensity modulated radiotherapy treatment plans. Med Dosim. 35:115–121. 2010.
9	Bertelsen A, Hansen CR, Johansen J and Brink C: Single arc volumetric modulated arc therapy of head and neck cancer. Radiother Oncol. 95:142–148. 2010.
10	Guckenberger M, Richter A, Krieger T, Wilbert J, Baier K and Flentje M: Is a single arc sufficient in volumetric-modulated arc therapy (VMAT) for complex-shaped target volumes? Radiother Oncol. 93:259–265. 2009.
11	Alvarez-Moret J, Pohl F, Koelbl O and Dobler B: Evaluation of volumetric modulated arc therapy (VMAT) with Oncentra MasterPlan^® for the treatment of head and neck cancer. Radiat Oncol. 5:1102010.
12	Edge SB and Compton CC: The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
13	International Commission of Radiation Units and Measurements. ICRU report 83: Prescribing, Recording, and Reporting Photon-Beam Intensity-Modulated Radiation Therapy (IMRT). Journal of the ICRU. 10:12010.
14	Liu GF, Bair RJ, Bair E, Liauw SL and Koshy M: Clinical outcomes for gastric cancer following adjuvant chemoradiation utilizing intensity modulated versus three-dimensional conformal radiotherapy. PLoS One. 9:e826422014.
15	Stieler F, Wolff D, Schmid H, et al: A comparison of several modulated radiotherapy techniques for head and neck cancer and dosimetric validation of VMAT. Radiother Oncol. 101:388–393. 2011.
16	Cozzi L, Dinshaw KA, Shrivastava SK, et al: A treatment planning study comparing volumetric arc modulation with RapidArc and fixed field IMRT for cervix uteri radiotherapy. Radiother Oncol. 89:180–191. 2008.
17	Fogliata A, Clivio A, Nicolini G, Vanetti E and Cozzi L: Intensity modulation with photons for benign intracranial tumours: a planning comparison of volumetric single arc, helical arc and fixed gantry techniques. Radiother Oncol. 89:254–262. 2008.
18	Wang X, Li G, Zhang Y, et al: Single-arc volumetric-modulated arc therapy (sVMAT) as adjuvant treatment for gastric cancer: Dosimetric comparisons with three-dimensional conformal radiotherapy (3D-CRT) and intensity-modulated radiotherapy (IMRT). Med Dosim. 38:395–400. 2013.
19	Murofushi K, Kitamura N, Machida H, et al: The impact of vicryl mesh sheet placed on pelvic wall for reducing the irradiated bowel volume in VMAT of cervical cancer: Planning study. Int J Radiat Oncol Biol Phys. 84:S430–S431. 2012.
20	Peschel RE, Chen M and Seashore J: The treatment of massive hepatomegaly in stage IV-S neuroblastoma. Int J Radiat Oncol Biol Phys. 7:549–553. 1981.
21	Cassady JR: Clinical radiation nephropathy. Int J Radiat Oncol Biol Phys. 31:1249–1256. 1995.
22	Jansen EPM, Saunders MP, Boot H, et al: Prospective study on late renal toxicity following postoperative chemoradiotherapy in gastric cancer. Int J Radiat Oncol Biol Phys. 67:781–785. 2007.
23	Emami B, Lyman J, Brown A, et al: Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 21:109–122. 1991.
24	Wang YB, Chen EQ, Cui YL, Zeng L, Wang YJ and Tang H: Seroprevalence of hepatitis B virus markers in individuals for physical examination in West China Hospital, China. Eur Rev Med Pharmacol Sci. 15:592–596. 2011.
25	Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS and Ten Haken RK: Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 53:810–821. 2002.
26	Liang SX, Zhu XD, Xu ZY, et al: Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys. 65:426–434. 2006.
27	Xu J, Zhu H, Zhao Y, et al: Factors associated with hepatic dysfunction in hepatitis B-positive patients with postgastrectomy adenocarcinoma. Oncol Lett. 4:471–476. 2012.
28	Singh AK, Tierney RM, Low DA, et al: A prospective study of differences in duodenum compared to remaining small bowel motion between radiation treatments: Implications for radiation dose escalation in carcinoma of the pancreas. Radiat Oncol. 1:332006.
29	Huang J, Robertson JM, Ye H, Margolis J, Nadeau L and Yan D: Dose-volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherapy for locally advanced pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 83:1120–1125. 2012.
30	Ahmadu-Suka F, Gillette EL, Withrow SJ, Husted PW, Nelson AW and Whiteman CE: Exocrine pancreatic function following intraoperative irradiation of the canine pancreas. Cancer. 62:1091–1095. 1988.
31	Yamaguchi K, Nakamura K, Kimura M, et al: Intraoperative radiation enhances decline of pancreatic exocrine function after pancreatic head resection. Dig Dis Sci. 45:1084–1090. 2000.
32	Hu W, Ye J, Wang J, Xu Q and Zhang Z: Incorporating breath holding and image guidance in the adjuvant gastric cancer radiotherapy: a dosimetric study. Radiat Oncol. 7:982012.